[{"address1": "Building C14", "address2": "4th Floor No. 218, Xinghu Street Suzhou Industrial Park", "city": "Suzhou", "zip": "215123", "country": "China", "phone": "86 512 8777 3632", "website": "https://www.adagene.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Adagene Inc., a clinical stage immunotherapy company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.", "fullTimeEmployees": 248, "companyOfficers": [{"maxAge": 1, "name": "Dr. Peter P.  Luo Ph.D.", "age": 57, "title": "Co- Founder, Chairman, CEO and President of R&D", "yearBorn": 1966, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Man Kin  Tam M.B.A.", "age": 46, "title": "CFO & Director", "yearBorn": 1977, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jc  Xu M.D., Ph.D.", "age": 58, "title": "Chief Scientific Officer", "yearBorn": 1965, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ami Celeste Knoefler", "title": "Vice President of Investor Relations & Corporate Communications", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ling  Zhou", "title": "Head of Human Resources", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Qinghai  Zhao", "age": 62, "title": "Chief Manufacturing Officer", "yearBorn": 1961, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Yan  Li M.B.A.", "age": 48, "title": "Senior VP of Bioinformatics & Information Technology and Director", "yearBorn": 1975, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Xiaohong  She", "age": 56, "title": "Senior VP & Head of Clinical Operations", "yearBorn": 1967, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Guizhong  Liu Ph.D.", "age": 52, "title": "Head of Biology & Pharmacology", "yearBorn": 1971, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alexander  Goergen", "age": 36, "title": "VP & Head of Business Development", "yearBorn": 1987, "exercisedValue": 0, "unexercisedValue": 0}], "maxAge": 86400, "priceHint": 4, "previousClose": 2.82, "open": 2.81, "dayLow": 2.71, "dayHigh": 2.97, "regularMarketPreviousClose": 2.82, "regularMarketOpen": 2.81, "regularMarketDayLow": 2.71, "regularMarketDayHigh": 2.97, "beta": 0.471, "forwardPE": -2.0583942, "volume": 26781, "regularMarketVolume": 26781, "averageVolume": 117750, "averageVolume10days": 32190, "averageDailyVolume10Day": 32190, "bidSize": 900, "askSize": 1200, "marketCap": 124409088, "fiftyTwoWeekLow": 1.1, "fiftyTwoWeekHigh": 4.38, "priceToSalesTrailing12Months": 5.4889684, "fiftyDayAverage": 3.13342, "twoHundredDayAverage": 1.84477, "currency": "USD", "enterpriseValue": 50995960, "profitMargins": -1.60765, "floatShares": 12955337, "sharesOutstanding": 44116700, "sharesShort": 21943, "sharesShortPriorMonth": 21687, "sharesShortPreviousMonthDate": 1705017600, "dateShortInterest": 1707955200, "sharesPercentSharesOut": 0.0005, "heldPercentInsiders": 0.0422, "heldPercentInstitutions": 0.16253, "shortRatio": 0.1, "shortPercentOfFloat": 0.0007, "impliedSharesOutstanding": 55744500, "bookValue": 1.889, "priceToBook": 1.4928533, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1688083200, "netIncomeToCommon": -36437856, "trailingEps": -0.86, "forwardEps": -1.37, "enterpriseToRevenue": 2.25, "enterpriseToEbitda": -1.298, "52WeekChange": 1.0735295, "SandP52WeekChange": 0.3288405, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "ADAG", "underlyingSymbol": "ADAG", "shortName": "Adagene Inc.", "longName": "Adagene Inc.", "firstTradeDateEpochUtc": 1612881000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "62e74ad1-53ab-3c04-9114-3e2ec68862ec", "messageBoardId": "finmb_118162960", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.82, "targetHighPrice": 26.0, "targetLowPrice": 4.6, "targetMeanPrice": 11.87, "targetMedianPrice": 5.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 128759960, "totalCashPerShare": 2.35, "ebitda": -39283776, "totalDebt": 25238704, "quickRatio": 3.312, "currentRatio": 3.403, "totalRevenue": 22665296, "debtToEquity": 30.484, "revenuePerShare": 0.523, "returnOnAssets": -0.16287, "returnOnEquity": -0.37280998, "revenueGrowth": 3.409, "grossMargins": 1.0, "ebitdaMargins": -1.73321, "operatingMargins": -0.29192, "financialCurrency": "USD", "trailingPegRatio": null}]